OS Therapies Incorporated (OSTX) Stock

OS Therapies Incorporated (OSTX) is a Healthcare stock trading at $1.50 (as of 2026-08-21), with a market capitalization of $69.19M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Understand OS Therapies Incorporated: how it makes money

OS Therapies Incorporated develops and commercializes treatments for osteosarcoma and other solid tumors, including OST-HER2 (an off-the-shelf immunotherapy) and OST-tADC (an antibody-drug conjugate technology), and it makes money only if these therapies progress from clinical development to commercialization.

As a clinical stage biopharmaceutical company, its ability to generate future profit depends on proving and advancing its pipeline (OST-HER2 and OST-tADC) through clinical milestones that support eventual commercialization for osteosarcoma and other solid tumors.

Business quality (Mixed): Clear product and platform focus (OST-HER2 and OST-tADC), but current period shows no reported revenue and the operating result is deeply negative, so value visibility depends heavily on clinical progress.

Bull case

  • Focused pipeline on osteosarcoma and other solid tumors: The company is targeting osteosarcoma with OST-HER2 and pursuing a tunable antibody-drug conjugate approach with OST-tADC, which may broaden its opportunity within solid tumors.
  • Trackable clinical trial execution metrics: The provided operational metrics include Event Free Survival and Phase 2b trial related measures (patients dosed and protocol-based enrollment/dosing), which can help investors monitor trial momentum.

Bear case

  • No reported revenue in the latest period: For the quarter ended 2026-03-31, revenue is shown as 0.0B, which means there is no confirmed commercialization contribution yet.
  • Operating losses remain extreme: The latest reported operating margin is deeply negative (operating_margin_pct is -22595417.8), indicating substantial ongoing costs relative to any current revenue generation.
Valuation — source: SEC EDGAR (first-party)
Price$1.50
Market Cap$69.19M
Price / Sales344222.57
FCF Yield-15.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$249.00
Net Margin-11547728.5%
Return on Equity330.4%
Debt / Equity-0.01
Current Ratio0.18
Financial Health — source: SEC EDGAR
Altman Z-Score-26.86 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($756589.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPaul A. Romness
Employees4
CountryUS
IPO Date2024-08-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Pliant Therapeutics, Inc. (PLRX)
  • Rein Therapeutics Inc. (RNTX)
  • Spero Therapeutics, Inc. (SPRO)
  • PMV Pharmaceuticals, Inc. (PMVP)
  • XBiotech Inc. (XBIT)
  • MediciNova, Inc. (MNOV)
  • Boundless Bio, Inc. (BOLD)
  • Cypherpunk Technologies Inc. (CYPH)
OSTX earnings history · OSTX institutional & insider holders · OSTX KPIs & operating metrics · OSTX financials · OSTX investor presentations & press releases · OSTX SEC filings · OSTX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.